Physician profile
Jihee Kim
NPI 1194395053
$5,495.19
in general payments reported to CMS, 2019-2025
26 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $87.86 · 2023: $1,775 · 2024: $2,078 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,407.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,214.07 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $869.47 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $788.37 | 2023-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $557.64 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.23 | 2023-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $218.51 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $175.34 | 2022-2025 | |
| Lilly USA, LLC | $153.30 | 2023-2025 | Jardiance, Mounjaro, Amyvid |
| Janssen Pharmaceuticals, INC | $147.08 | 2023-2024 | Xarelto |
| Aimmune Therapeutics, INC. | $140.99 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $134.95 | 2024 | Voquezna |
| Dexcom, INC. | $110.13 | 2023-2024 | Dexcom G6 Transmitter |
| Vivus LLC | $106.44 | 2022-2025 | Pancreaze |
| Exact Sciences Corporation | $86.53 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $69.15 | 2023-2025 | Rybelsus, Ozempic |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $66.44 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $64.97 | 2022-2024 | Linzess |
| Pfizer INC. | $64.64 | 2023-2025 | |
| Esperion Therapeutics, INC. | $62.48 | 2024-2025 | Nexletol |
| Ardelyx, INC. | $54.83 | 2024-2025 | Ibsrela |
| Lundbeck LLC | $39.21 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $39.06 | 2023-2024 | Rexulti |
| Eisai INC. | $25.04 | 2024 | |
| Philips North America LLC | $17.04 | 2023 | |
| Paratek Pharmaceuticals, INC. | $16.26 | 2023 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $16.02 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jihee Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.